CRISPR Therapeutics: A Speculative Play On The Future Of Medicine

Apr. 19, 2021 3:39 PM ETCRISPR Therapeutics AG (CRSP)17 Comments
Star Investments profile picture
Star Investments


  • CRISPR Therapeutics stock reached a 52-week high of $220.20 in Jan 2021 and has since fallen significantly down to $114.39 as of Apr 12, 2021.
  • Rising treasury yields sparked by inflation fears is part of the reason investors have retreated from speculative stocks like CRISPR Therapeutics recently.
  • CRISPR Therapeutics is an early-stage "Story Stock", whose stock price moves more on news about the therapy pipeline than it does on company fundamentals.
  • This company is a buy but only for investors that have high risk tolerance and are able to withstand the volatility.

DNA and genome editing
Photo by elenabs/iStock via Getty Images

2020 was the Year

2020 was the year that the science of CRISPR really began getting recognized as making progress in becoming a potential breakthrough medical technology. CRISPR-Cas9 is a technology that can be

This article was written by

Star Investments profile picture
I have been a Merchant Seaman that has traveled the world for over 30 years. Within the last 15 years, I developed a very intense interest in investing. I learned a lot of what I know about investing from The Motley Fool. Also because I have a engineering background, I often tend to gravitate to Tech stocks

Disclosure: I am/we are long CRSP. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (17)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.